Epi-genetics and treatment planning for primary glioblastoma

International Conference and Exhibition on Molecular Medicine and Diagnostics

August 24-26, 2015 London, UK

Rasime Kalkan

Posters-Accepted Abstracts: J Mol Genet Med

Abstract :

Background: To establish the frequency of MGMT and RARβ methylation in primary glioblastomas. We screened primary
glioblastoma multiforme (GBM) in a population-based study for MGMT and RARβ methylation and correlated them with clinical
data and treatment.
Results: MGMT methylation was detected in 13 of the 40 patients (32.5%). MGMT-promoter methylation did not correlate with
overall survival (OS; p>0.05). RARB methylation was detected in 24 of the 40 patients (60%). The overall survival time of the patients
with methylated RARβ was 19 months, and non-methylated RARB was 15 months. There was statically (OS; p<0.05) significance
between the patients who were treated with chemotherapy and radiotherapy.
Conclusion: In summary, this study is suggested to the RARβ gene is also a new prognostic and predictive candidate marker for the
primary GBM patients for choosing therapy strategy. Furthermore MGMT promoter methylation had no prognostic value and lower
frequency in primary glioblastomas.